The universal immunization of infants and toddlers with pneumococcal conjugate vaccine
(PCV) in the United States beginning in 2000 heralded a new era for pneumococcal disease …

Pneumococcal disease is a leading cause of childhood mortality, globally. The
pneumococcal conjugate vaccine (PCV) has been introduced to many countries worldwide …

The efficacy of the serotype 3 (ST3) pneumococcal conjugate vaccine (PCV) remains
unclear. While the synthesis of capsular polysaccharide (CPS) of most serotypes is wzy …

BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in
the United States in 2010. We describe invasive pneumococcal disease (IPD) in children at …

The aim of this study was to investigate the serotype-associated fatality rate in cases of
invasive pneumococcal disease (IPD) in the Spanish region of Madrid between 2007 and …

BACKGROUND Children with sickle cell disease (SCD) are at increased risk for
bloodstream infections (BSIs), mainly because of functional asplenia. Immunizations and …

Background The objective of this study is to evaluate rates of all-cause pneumonia among
“at-risk” and “high-risk” children and adults in Germany—in comparison with age-stratified …

Background Following the introduction of pneumococcal conjugate vaccines (PCV), overall
nasopharyngeal colonization rates have not changed significantly, however a dramatic and …

Objectives To explore the serotype distribution and drug resistance patterns of invasive
pneumococcal isolates from children under 5 years of age. Methods During a 32-month …

Background: For the scarcity of data, we investigated the vaccine effectiveness (VE) of the
combined use of pneumococcal conjugate vaccines (PCVs) of different valences against …